EO14042-TOPIC 429 A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURINGPERIOD OF PERFORMANCE SEPTEMBER 13, 2021-JUNE 21, 2022FY21 PH

Proteios Technology has developed a proprietary platform that does not rely on antibodies nor magnetic beads to isolate cell subpopulations. The platform has been validated on T cells using the CD4+ and CD8+ subpopulations for the production of autologous CAR-T cell therapies. They are currently extending the platform for the isolation of Natural Killer (NK) cells for the production of autologous CAR-NK cell therapies and allogeneic NK cell therapies. Phase I of the proposal will allow Proteios to construct a bench prototype to validate the scale-up of their platform for the production of CAR-T cell therapies and for benchmarking against current manufacturing methods. Proteios’ modular approach will provide the flexibility to adapt to new approaches to cell therapies as researchers are able to isolate new cell subpopulations with their research instrument. Proteios’ vision is to move on to construct an at-scale cGMP prototype and apply their technologies to help lower the cost of healthcare therapies, including cell therapies and gene therapies.